secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001683168-24-003550
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma Q1 net loss $3.5M; Berubicin GBM trial topline data H1 2025
----------------------------------------------------------------------

- Net loss $3.5M for Q1 2024, vs $4.9M in Q1 2023; R&D expense down to $2.4M from $3.6M.
- Cash at March 31, 2024 was ~$0.8M; no revenue reported.
- Enrollment completed in potentially pivotal Berubicin trial for GBM; DSMB recommended continuation in Dec 2023.
- Topline data from Berubicin study expected first half 2025.
- FDA granted Fast Track and Orphan Drug designations for Berubicin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer